Specific targeting of peripheral serotonin 5-HT3 receptors. Synthesis, biological investigation, and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 52, Issue 11, 2009, Pages 3548-3562

  Morelli, Elena ^a,c   Gemma, Sandra ^a,b   Budriesi, Roberta ^d   Campiani, Giuseppe ^a,b,f   Novellino, Ettore ^a,c   Fattorusso, Caterina ^a,c   Catalanotti, Bruno ^a,c   Coccone, Salvatore Sanna ^a,b   Ros, Sindu ^a,b   Borrelli, Giuseppe ^a,b   Kumar, Vinod ^a,b   Persico, Marco ^a,c   Fiorini, Isabella ^a,b   Nacci, Vito ^a,b   Ioan, Pierfranco ^d   Chiarini, Alberto ^d   Hamon, Michel ^e   Cagnotto, Alfredo ^a,f   Mennini, Tiziana ^a,f   Fracasso, Claudia ^a,f   Colovic, Milena ^a,f   Caccia, Silvio ^a,f   Butini, Stefania ^a,b   more..

^a European Research Centre for Drug Discovery and Development   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e INSERM   (France)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(4 QUINOLIN 2 YLPIPERAZIN 1 YL)ACETIC ACID; 2 [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]ACETAMIDE; 2 [4 (9 METHYLPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL] 2 PHENYLETHANOL; 2 AMINO 1 [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL] 3 HYDROXYPROPAN 1 ONE; 2 AMINO 3 [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]PROPIONIC ACID; 5 [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YLMETHYL] 3H [1,3,4]OXADIAZOL 2 ONE; 7 FLUORO 4 [4 (1H TETRAZOL 5 YL)METHYLPIPERAZIN 1 YL]PYRROLO[1,2 A]QUINOXALINE; 7 FLUORO 4 [4 (2,3 DIHYDRO 4H 3 OXO 1,2,4 TRIAZOL 5 YL)METHYLPIPERAZIN 1 YL]PYRROLO[1,2 A]QUINOXALINE; 7 FLUORO 4 [4 (4H[1,2,4]TRIAZOL 3 YLMETHYL)PIPERAZIN 1 YL]PYRROLO[1,2 A]QUINOXALINE; 7 FLUORO 4 [4 (METHANESULFONAMIDOACETYL)PIPERAZIN 1 YL]PYRROLO[1,2 A]QUINOXALINE; [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]ACETIC ACID; [4 (7 FLUOROPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]HYDROXYACETAMIDE; [4 (7 HYDROXYPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]ACETIC ACID; [4 (9 METHYLPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]HYDROXYACETAMIDE; [4 (9 METHYLPYRROLO[1,2 A]QUINOXALIN 4 YL)PIPERAZIN 1 YL]PHENYLACETIC ACID; PYRROLOQUINOXALINE DERIVATIVE; QUINOXALINE DERIVATIVE; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR REFLEX; CHRONOTROPISM; CONTROLLED STUDY; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; INOTROPISM; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BAROREFLEX; FEMALE; GUINEA PIGS; HEART; HEART ATRIA; MALE; MICE; MODELS, MOLECULAR; MYOCARDIUM; PHYSICOCHEMICAL PHENOMENA; PYRROLES; QUINOXALINES; QUIPAZINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66749106830     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900018b     Document Type: Article

References (63)

1. 3 serotonin receptors: a structure-affinity investigation. Bioorg. Med. Chem. Lett. 2001, 11, 1599-1603.
2. 3 receptors as therapeutic target. Expert Opin. Ther. Targets 2007, 11, 527-540.
3. Collingridge, G. L.; Olsen, R. W.; Peters, J.; Spedding, M. A nomenclature for ligand-gated ion channels. Neuropharmacology 2009, 56, 2-5.
4. 3E. Mol. Pharmacol. 2007, 72, 8-16.
5. 3 receptor, the relationship between structure and function. Neuropharmacology 2009, 56, 273-284.
6. 3 receptor network after 20 years of research. Evolving concepts in management of pain and inflammation. Eur. J. Pharmacol. 2007, 560, 1-8.
7. Stevens, R.; Rusch, D.; Solt, K.; Raines, D. E.; Davies, P. A. Modulation of human 5-hydroxytriptamine type 3AB receptors by volatile anesthetics and alcohols. J. Pharmacol. Exp. Ther. 2005, 314, 338-345. (Pubitemid 41058271)
8. Krzywkowski, K.; Davies, P. A.; Irving, A. J.; Bräuner-Osborne, H.; Jensen, A. A. Characterization of the effects of four HTR3B polymorphisms on human 5-HT3AB receptor expression and signalling. Pharmacogenet. Genomics 2008, 18, 1027-1040, and references cited therein.
9. Ramage, A. G.; Villalón, C. M. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol. Sci. 2008, 29, 472-481.
10. Nishio, H.; Fujii, A.; Nakata, Y. Re-examination for pharmacological properties of serotonin-induced tachycardia in isolated guinea-pig atrium. Behav. Brain Res. 1996, 73, 301-304. (Pubitemid 26008802)
11. 3 receptor agonist, in vitro. Eur. J. Pharmacol. 2000, 409, 195-201.
12. 3 receptor agonists based on a pyrroloquinoxaline structure. J. Med. Chem. 1997, 40, 3670-3678.
13. 3 receptor agonists: synthesis, further structure-activity relationships, and biological studies. J. Med. Chem. 1999, 42, 4362-4379.
14. 3 receptor sites. Med. Chem. Res. 1996, 6, 81-101.
15. 3 receptor ligand showing potent acetylcholinesterase inhibitory properties. J. Med. Chem. 2005, 48, 3564-3575.
16. 2 receptor antagonists. Synthesis of N-cyano and carbamoyl amidine derivatives and their biological activities. J. Med. Chem. 1984, 27, 849-857.
17. Arnold, L. D.; Kalantar, T. H.; Vederas, J. C. Conversion of serine to stereochemically pure β-substituted R-amino acids via β-lactones. J. Am. Chem. Soc. 1985, 107, 7105-7109. (Pubitemid 16206091)
18. 4 receptor antagonists. Med. Res. Rev. 1997, 17, 163-214, and references therein.
19. 3 receptor antagonists and a definition of a model for this receptor site. J. Med. Chem. 1990, 33, 1594-1600.
20. 3 receptor ligands. Pharmacol., Biochem. Behav. 1991, 40, 1033-1040.
21. 3 antagonists. Indole oxadiazoles. J. Med. Chem. 1991, 34, 140-151.
22. 3 receptor antagonists. J. Med. Chem. 1990, 33, 2101-2108.
23. 3 receptor antagonists. J. Med. Chem. 1993, 36, 2645-2657.
24. (g) Whelan, B. A.; Iriepa, I.; Galvez, E.; Orjales, A.; Berisa, A.; Labeaga, L.; Garcia, A. G.; Uceda, G.; Sanz-Aparicio, J.; Fonseca, I. Synthesis and structural, conformational, biochemical, and pharmacological study of new compounds derived from tropane-3-spiro-4′(5′)-imidazoline as potential 5-HT3 receptor antagonists. J. Pharm. Sci. 1995, 84, 101-106. (Pubitemid 26068399)
25. 3 and β2-adrenergic receptors. J. Med. Chem. 1995, 38, 4080-4086.
26. (i) Glennon, R. A.; Westkaemper, R. B.; Bartyzel, P. Medicinal Chemistry of Serotonergic Agents. In Serotonin Receptor Subtypes: Basic & Clinical Aspects; Peroutka, S. J., Ed.; Wiley-Liss: New York, 1990;
27. Recept. Biochem. Method. Ser. 1990, 15; 19-64.
28. 3 receptor agonist activity in the gut. Chem. Pharm. Bull. 1998, 46, 445-451.
29. Steward, L. J.; Boess, F. G.; Steele, J. A.; Liu, D.; Wong, N.; Martin, I. L. Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine(3A) receptor. Mol. Pharmacol. 2000, 57, 1249-1255. (Pubitemid 30354398)
30. 3 receptor. Mol. Membr. Biol. 2006, 23, 442-451.
31. 3ASR binding site. BMC Biochem. 2002, 3, 15.
32. Price, K. L.; Lummis, S. C. The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine3 receptor. J. Biol. Chem. 2004, 279, 23294-23301. (Pubitemid 38685638)
33. 3A receptor model. Biochemistry 2006, 45, 1099-1105.
34. 3R antagonist. BMC Biochem. 2002, 3, 16.
35. Cappelli, A.; Anzini, M.; Vomero, S.; Mennuni, L.; Makovec, F.; Hamon, M.; De Benedetti, P. G.; Menziani, M. C. The interactions of the 5-HT(3) receptor with arylpiperazine, tropane, and quinuclidine ligands. Curr. Top. Med. Chem. 2002, 2, 599-624.
36. 3 receptor extracellular domain: a search for ligand binding sites. Theor. Chem. Acc. 2001, 106, 98-104.
37. 3AB receptors by agonists. J. Comput.-Aided Mol. Des. 2004, 18, 651-664.
38. 3 receptor agonist-binding residues using homology modelling. Biophys. J. 2003, 84, 2338-2344.
39. 3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacology 1997, 36, 637-647.
40. 3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 2002, 41, 10262-10269.
41. Maksay, G.; Bikadi, Z.; Simonyi, M. Binding interactions of antagonists with 5-hydroxytryptamine3A receptor models. J. Recept. Signal Transduction Res. 2003, 23, 255-270. (Pubitemid 37362244)
42. Yan, D.; White, M. M. Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT3 receptor. Mol. Pharmacol. 2005, 68, 365-371. (Pubitemid 41058300)
43. 3 receptor antagonists. J. Mol. Model. 2007, 13, 121-131.
44. 3 receptor. J. Biol. Chem. 1999, 274, 5537-5541.
45. 3 receptor binding site using modelling and radioligand binding. J. Biol. Chem. 2005, 280, 20476-20482.
46. 3 receptor ligand binding domain. J. Biol. Chem. 2000, 275, 5620-5625.
47. 3A receptor contributes to the differential actions of 5-hydroxytryptamine and m-chlorophenylbiguanide. Biochemistry 2005, 44, 9140-9149.
48. 3 receptor antagonist properties of ICS 205-930, GR38032F and Zacopride. J. Pharmacol. Exp. Ther. 1989, 248, 197-201.
49. Caccia, S.; Garattini, S. Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clin. Pharmacokinet. 1990, 18, 434-459. (Pubitemid 20183887)
50. Caccia, S. N-Dealkylation of 1-arylpiperazine derivatives: disposition and metabolism of the 1-arylpiperazines formed. Curr. Drug Metab. 2007, 8, 612-622. (Pubitemid 47209098)
51. 3 receptor antagonists based on the arylpiperazine skeleton: synthesis, structure, biological activity, and comparative molecular field analysis studies. J. Med. Chem. 1995, 38, 2692-2704.
52. Campiani, G.; Butini, S.; Gemma, S.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Giorgi, G.; Cagnotto, A.; Goegan, M.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. J. Med. Chem. 2002, 45, 344-359. (Pubitemid 34073452)
53. 2 receptors. J. Med. Chem. 2003, 46, 3822-3839.
54. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Serio, S. D.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. 2004, 47, 143-157. (Pubitemid 38040498)
55. CVFF: Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins: Struct., Funct., Genet. 1998, 4, 31-47.
56. Fletcher, R. Unconstrained Optimization. In Pratical Methods of Optimization; John Wiley & Sons: New York, 1980; Vol.1.
57. (a) Stewart, J. J. P. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
58. (b) Stewart, J. J. P. MOPAC2007; Stewart Computational Chemistry: Colorado Springs, CO, 2007; HTTP://OpenMOPAC.net.
59. Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic Calculations with Computer Programs, 2nd ed.; Springer-Verlag: New York, 1987.
60. Motulsky, H.; Christopoulos, A. Fitting Models to Biological Data Using Linear and Non Linear Regression. www.GraphPad.Com, 2003.
61. Motulsky, H. Statistic Guide: Statistical Analysis for Laboratory and Clinical Research: A Pratical Guide to Curve Fitting. www.GraphPad.com, 2003.
62. Arunlakshana, D.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
63. 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979, 25, 637-654.